No Association Between Adalimumab Use and Heart Failure in Patients with Hidradenitis Suppurativa: A Propensity Matched Study

Published: 29 October 2024| Version 1 | DOI: 10.17632/j9fdbxk72x.1
Contributors:
,
, Charles DeYoung,
,
,

Description

Background: Adalimumab, a tumor necrosis factor alpha inhibitor, is linked to heightened heart failure (HF) risk, particularly in patients with immune dysregulation. Hidradenitis suppurativa (HS) is associated with high cardiovascular comorbidities and has limited treatments, with adalimumab being one. Despite these connections, research on HF risk in HS patients treated with adalimumab is limited. Objective: To ascertain if HS patients treated with adalimumab are more prone to developing new or worsening HF compared to those not receiving adalimumab. Methods: A retrospective cohort study was conducted using TriNetX from September 2015 to May 2023, analyzing 121,854 HS patients without pre-existing HF. The “Adalimumab Group” included 4,645 HS patients, and the “No Adalimumab Group” comprised the remaining 117,209. Another analysis identified 4,399 HS patients with pre-existing HF, with 155 receiving adalimumab. The study assessed the 1-year risk of new-onset HF among these patients. Results: No significant difference in the risk of new or worsening HF were observed. Limitations: This study's reliance on administrative claims databases limits detailed clinical context, confirmation of medication dosage and compliance, and introduces potential coding errors. Conclusions: This first large-scale study suggests adalimumab treatment may not elevate the risk of new or worsening HF in HS patients.

Files

Institutions

Thomas Jefferson University

Categories

Tumor Necrosis Factor, Biologic Therapy, Heart Failure, Cardiovascular Disease Risk Factor, Inflammatory Disorder, Hidradenitis Suppurativa

Licence